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The clinical practice guideline (CPG) is the implementation of a depression screening 
tool to be used in the early perinatal period. The practice change occurred in a rural 
Obstetrical and Gynecological (OBGYN) practice in the southern United States. The 
CPG change has been guided by recommendations from both the American Congress 
of Obstetrics and Gynecology and the American College of Nurse Midwives. 
Implementation of this CPG change addresses the gap in practice of not doing 
depression screening during the perinatal period, and only screening during the 
postpartum period, which was being done at the OBGYN office. Theorist Lewin’s 
‘change theory’ guided the implementation of the project.  In order to apply this 
project, a process of changing practice guidelines was needed at the OBGYN office.  
The DNP project presented the practice change guideline of implementing the 
Edinburgh Postpartum Depression Screening (EPDS) tool. The need for the CPG 
development was evaluated by 3 nurse leaders using the AGREE II tool and was 
recommended 100% without modifications by all 3 evaluators. The CPG, with the 
results, was presented and discussed with the practice site’s practitioners.  The 
practitioners implemented the EPDS to be given at the 12- week checkup 
appointment versus the confirmation of pregnancy appointment, which was suggested 
through the DNP project’s CPG.  The implementation of this CPG has the potential to 
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Section 1: Introduction 
Introduction 
According to the American Congress of Gynecology (ACOG) and the American 
College of Nurse Midwives (ACNM), recommendations are in support of using 
depression-screening tools during the early perinatal period.  At the practicum site, 
depression screening was only done during the postpartum period.  The Doctor of 
Nursing Practice (DNP) project, proposes the use of the Edinburgh Postpartum 
Depression Screening (EPDS) Appendix B, at the confirmation of pregnancy 
appointment.  
Problem Statement 
The DNP project is a clinical practice guideline (CPG) change to implement the 
use of the EPDS tool, to be used during the early perinatal period in an obstetrical and 
gynecological (OBGYN) provider practice.  The Institute of Medicine (IOM) defined 
clinical practice guidelines as “statements that include recommendations intended to 
optimize patient care that are informed by a systematic review of evidence and an 
assessment of the benefits and harms of alternative care options” (Institute of Medicine, 
2011, p. 26).  According to ACOG (2015), identifying pregnant and postpartum women 
with depression is important because untreated perinatal depression can have devastating 
effects on women, infants, and families.  The OBGYN clinic was only doing a 
postpartum screening during the postpartum period.  The gap in practice at the practicum 





The objective of this CPG was to provide all pregnant women at the local 
OBGYN practice with a depression screening tool, specifically the EPDS, during the 
early perinatal period. 
Practice-Focused Question/PICO 
In perinatal clients within a rural OB/GYN practitioner’s outpatient office in the 
southern United States, how does providing a depression screening tool (EPDS) during 
the early perinatal period align with recommendations from ACOG, ACNM and a review 
of current literature, compare to the existing guidelines of the OBGYN office and 
improve client’s care?  
  The purpose of this project is to develop a proposed guideline change to be 
implemented during the early perinatal period and provide the OBGYN clinic with 
information on the need for the clinical practice guideline change.  
Goal: Provide the CPG change with recommendations from ACOG, ACNM, a review 
of current literature, and an evaluation using the AGREE II tool, to implement a 
depression screening tool, the EPDS, to perinatal women during their ‘confirmation of 
pregnancy’ appointment, at the OBGYN clinical practice site. 
1. Objective 1: The DNP student will address the CPG problem: no screening 
guidelines of perinatal clients for depression, by initiating the use of the EPDS at 
the ‘confirmation of pregnancy’ visit. 
2. Objective 2: The DNP student will apply recommended clinical practice 
guidelines from the ACOG and the ACNM into the area of evidence basis of early 




3. Objective 3: The DNP student will demonstrate the achievement of learning 
objectives related to the AACN DNP Essentials, VI. Interprofessional 
Collaboration for Improving Patient and Population Health Outcomes and VII. 
Clinical Prevention and Population Health for Improving the Nation’s Health 
(DNP Essentials, 2006), by creating a CPG of providing a depression screening 
tool during the early perinatal period 
Purpose Statement  
The need for an effective screening tool to evaluate pregnant women during the 
perinatal and postpartum period is vital.  A CPG change, to include a perinatal depression 
screening, the EPDS tool, will be given to the clients at their confirmation of pregnancy 
appointment.  The EPDS will be included in their intake packet.  
Nature of the Doctoral Project 
The problem of post-partum depression (PPD) is global and has been diagnosed 
for more than one-hundred years (Bergink, Rasgon, & Wisner, 2016).  Esquirol described 
the first appearance of PPD (Bergink et al., 2016).  Esquirol described 92 women with 
postpartum psychosis, of which 53% had predominantly manic symptoms, 38% had 
depressive symptoms, and 9% had nonaffective psychosis (Bergink et al., 2016). 
Ambrosini, Donzelli, and Stanghellini (2012) described personality traits associated with 
postpartum depression perceived during the perinatal period.  The need for perinatal 
depression screening was proposed to help identify women who are at high risk for 
developing PPD and to begin treatment antepartum (Ambrosini et al., 2012).  The 




impact the potential increase in risk for depression in perinatal women and that the 
chronic stress associated with pregnancy may also lead to an increased chance for 
perinatal depression (Latendresse, Elmore, & Deneris, 2017).  According to ACOG 
(2017), as many as one in seven women may have perinatal depression or PPD.  A global 
public health study done in 2009 affirmed that PPD is a more significant problem than 
first thought; the rates globally for PPD are higher than 10%—15% of all pregnant 
women (Almond, 2009).  However, this percentage may be an underestimate of the actual 
existence of depression, given the social and cultural stigma about mental health 
(Latendresse et al., 2017).  
The postpartum period or puerperal period is considered from immediately after 
childbirth to 6 weeks post-birth.  However, after reviewing the literature, studies are 
considering pregnancy-related deaths, up to 1-year post-birth as associated with PPD 
(Palladino, Singh, Campbell, Flynn, & Gold, 2011).  A 2001 study showed that only one 
in five pregnant women who had a previous diagnosis of depression were screened 
during pregnancy for depression and had documentation of receiving treatment for 
depression (Kelly, Zatzick, & Anders, 2001).  A challenge with a depression diagnosis 
before pregnancy is that women may not want to continue with treatment, especially 
pharmacological, due to effects on the fetus (Latendresse et al., 2017).  Another study of 
perinatal clients screened for depression in obstetric settings reported that 20% of those 
women scored above the cut off (of the depression scale used), but only 13.8% of those 
women reported receiving any treatment for depression (Miller, Shade, & Vasireddy, 




preventable cause of maternal and infant mortality (Kendig, 2017).  According to Rope 
(2013), one in five women had thoughts of harming themselves during their pregnancies.  
With screening, these women could have been treated.  Suicide is the second leading 
cause of death in postpartum women, according to Palladino et al. (2011).  In a study 
conducted from 2003-2007 by Palladino, (2011) he determined that there was a 
pregnancy-associated suicide rate of 2.0 per 100,000 live births, 43% which occurred 
during the pregnancy and 50% which occurred postpartum. (see Appendix C).  
Significance 
The indications of perinatal depression and PPD may go unnoticed due to the 
vague symptoms noted by the women or their unwillingness to discuss it with their 
provider (Palladino et al., 2011).  Some of these symptoms could be related to a normal 
pregnancy.  Symptoms such as changes in appetite, sleep disturbances, and changes in 
libido could be considered normal changes during pregnancy (ACOG, 2017).  Risk 
factors for perinatal depression are  (a) maternal anxiety, (b) life stress, (c) history of 
depression, (d) lack of social support, (e) unintended pregnancy, (f) Medicaid insurance, 
(g) domestic violence, (h) lower income, (i) lower education, (j) smoking, (k) single 
status, and (m) poor relationship quality (ACOG, 2017).  According to ACOG (2017), 
perinatal depression is a widespread complication of pregnancy with potentially 
overwhelming consequences if it goes unrecognized and untreated.  Screening women in 
the early perinatal period might provide the healthcare practitioner foresight into 




pregnant woman and treat her proactively could potentially help decrease the problem of 
postpartum depression. According to Rope (2013),  
Thirty percent of the women who showed signs of depression after delivery had 
experienced an episode of the condition before pregnancy, 40 percent had one 
during pregnancy, and more than two-thirds of the women also had signs of an 
anxiety disorder, the symptoms of which are not often associated with depression. 
(p. 1) 
The United States Preventive Services Task Force’s (USPSTF, 2016) evaluation of 
women who had previously been given an EPDS in primary care offices, and were shown 
to have depression, were followed and re-evaluated during their pregnancy for 
depression.  A percentage of the women had interventions with pharmacological and 
counseling visits during the pre-and postpartum phases (USPTF, 2016).  There were 
different variables in effect during these studies, but the results were reasonably 
consistent across the range of designs, there was a decrease in symptoms of depression 
noted when the client followed the chosen intervention (USPSTF, 2016).  
Potential effects on both maternal and child health represent essential safety 
issues. Perinatal depression has been associated with adverse pregnancy and neonatal 
outcomes, including insecure maternal-newborn attachment (Kendig, 2017), eventually 
ending in increased mental health issues for the mother that could potentially affect the 
newborn.  
The EPDS is the most commonly used screening questionnaire for PPD (Gibson, 




Peterson, Squires, and Fortier (2017), “The EPDS was created specifically to screen for 
perinatal depression” (p. 1). The EPDS is an exam that consists of 10 self-reported items. 
The tool takes less than 5 minutes to complete; it has been translated into 12 languages, 
has a low required reading level, and is easy to score (ACOG, 2015).  When choosing a 
screening tool, cost, availability, ease of administration, and interpretation along with 
validity and acceptability are some of the characteristics that should be offered (Kendig, 
2017).  The usefulness of the EPDS is its free availability, simplicity of administration, 
and its general acceptability to women.  Therefore, this remains a useful tool in the field 
of perinatal mental health (Gibson et al., 2009).  In a study done by Friesen et al., the 
EPDS tool was found to be valid, reliable, and acceptable for perinatal women.  Ensuring 
the use of the EPDS for the DNP project would be effective.   
Summary 
 PPD and perinatal depression are a population health problem that could be 
prevented or decreased by following the guidelines presented by the ACOG.  Perinatal 
depression is an increasingly recognized maternal mental health problem (ACOG, 2017). 
Diagnosing and treating maternal mental health issues is critical in providing maternal 
safety (Kendig, 2017).  Due to indicators and expert medical recommendations, the need 
to create a CPG change by implementing a perinatal depression tool is essential in this 
OBGYN clinical practice.  After meeting with the providers of the OBGYN practice, it 
was decided to require the EPDS during the early perinatal period, at the confirmation of 
pregnancy appointment.  The EPDS will be part of the intake information for the client at 




for the use and results of the EPDS as a collaborative effort by the DNP student, the 




Section 2: Theories, Evidence, and Review of Literature 
Introduction 
The sequence of depressive illness with the onset during the perinatal period, 
including the severe physiologic and psychological dilemmas which provide unique 
challenges to this time period, are likely to complicate the identification and management 
of perinatal depression (Gaynes et al., 2005).  In 2016, ACOG recommended depression 
screening during the perinatal period (ACOG, 2017).  
Concepts, Models, and Theories 
The nursing theory for the DNP project is Lewin’s (1947) change theory.  Lewin 
observed that three stages that need to occur for a change to happen (Mitchell, 2017). The 
first is unfreezing, being able to see, through an evidence basis, the need for a change 
(Mitchell, 2013).  Second is moving, when the change is introduced, and third is 
refreezing, making the changes permanent, and establishing the new way (Mitchell, 
2013).  For this CPG, implementing the EPDS during the early perinatal period is the 
protocol change.  
The nursing process of assessment, planning, implementation, and evaluation is 
also a process for this CPG.  Considering evidenced-based information, from 
recommendations from ACOG and ACNM, the need for a depression screening to be 
used during the perinatal period, is essential.  Following the assessment, the nurse 
collaborates with the OBGYN practice providers and nurse leaders to determine how to 
address this need as a plan.  Implementation of the CPG change and evaluation of the 




stages of change can be resistance from staff, and financial barriers, among other 
obstacles (Flood, 2017).  A good nurse leader is beneficial when discussing changes with 
staff (Flood, 2017).  The EPDS is currently used at the practicum site and it is readily 
available so there is no extra financial burden.  Therefore, the use of a tool, already being 
utilized by the staff, with their understanding of the tool would be practical to implement, 
with no added expense to the facility and client.  
Relevance to Nursing Practice 
 The practice of nursing is to improve patient care and safety through evidence-
based occurrences (Melnyk, 2013).  By using this CPG, the OBGYN practice providers 
can diagnose and treat clients for depression earlier in their pregnancies, it will provide 
an improved outcome.  Through literature review and studies done on postpartum 
depression, it is noted that many of the clients should have been given depression 
screenings during their pregnancies.  If the women had been provided with screening 
during their perinatal period, it might have provided a better outcome for the clients and 
their families (see Fura, 2014).  
Local Background and Context 
 After discussing this problem with my preceptor, the conclusion was to offer the 
DNP project as a CPG change.  I made suggestion of implementing a perinatal depression 
screening to all pregnant women during the early perinatal period, and encouraging the 
recommended implementation from both, ACOG, and ACNM for depression screening in 




during the postpartum period. The EPDS tool is currently used at 1-2 weeks postpartum 
and again at 6 weeks postpartum.  
Role of the DNP Student 
 The role of the DNP student related to this project was to provide evidence-based 
information on the practice problem of perinatal depression at a local OBGYN practice.  I 
became interested in this project while being involved in precepting nursing students in 
their obstetrical and gynecological clinical rotations.  I am currently a nurse educator for 
both LVN/LPNs and BSN, RN students.  The topic of postpartum depression came up in 
one of the postclinical discussions.  Reviewing articles on perinatal depression, it was 
evident that many OBGYN clinics and facilities were not adhering to the 
recommendations of ACOG for depression screening during the perinatal period. 
Discussing this CPG change with a nurse midwife at the local OBGYN clinic, 
preparations were discussed to present the implementation of a perinatal depression 
screening tool.  
The role of the DNP student, according to DNP Essentials VII, is to help with 
“clinical prevention and population health for improving the nation’s health” (DNP 
Essentials, 2006 p. 15). Implementing this CPG will encourage the OBGYN practice to 
adhere to evidenced based practice changes, from ACOG and ACNM.  
Develop Evidence Selection Criteria 
In this literature review, I examined the use of a depression screening tool during 
the perinatal period and explored literature for research that will support the need for 




perinatal depression and risk factors that may lead to perinatal depression and the 
recommended perinatal depression screening tool that was used.  Additionally, I 
researched studies that demonstrated barriers or challenges to the research that may 
dissuade perinatal depression screening.  I also explored research that discussed the use 
of perinatal depression in different states in the United States and their mandates for 
perinatal depression screening.  
Search Literature Description 
Several combinations of search terms were used to search the current literature. 
Those key terms searches were perinatal depression, pregnancy and suicide, mental 
health and pregnancy, postpartum depression, pregnancy related depression screening 
tools, treatment for perinatal depression, depression tools for pregnant women, baby 
blues, depression screening, and states with recommended or mandated perinatal 
depression screening and depression. 
These terms were entered into several relevant nursing databases, of CINAHL 
plus, MEDLINE full text, Google scholar, PubMed, ACOG website, ACNM website, 
JAMA website NIH, IOM, USPSTF, and perinatal depression blogs.  Most of the 28 
resources gathered for the review used current literature from within the last 13 years. 
ranging from 2005-2018.  The resources were mainly current peer-reviewed journal 
articles; however, web articles, radio interviews, and blogs were also accessed to relate to 




The overall exclusion criteria for this literature review was maternal depression 
with an onset greater than one year postpartum and articles not written in English and 
without an English abstract.  
I delineated the sections of the literature review into three parts. I reviewed 
literature in connection with the need for perinatal depression screening, the 
qualifications for the use of the EPDS for perinatal depression screening, and the barriers 
and challenges perceived to dispute the necessity and appropriateness of perinatal 
depression screening. 
Critical Appraisal of the Literature  
According to Latendresse et al. (2017), 6-30% of pregnant women have perinatal 
depression, which corresponds to research in ACOG and the NIH and estimated the 
problem as one in seven women (ACOG, 2017). ACOG has recommended perinatal 
depression screening since 2015 and by ACNM since 2003 (ACNM, 2013).  However, in 
the 2003 ACNM recommendations, there were no parameters for screening frequency, 
tools, or referrals for treatment.  The 2015 recommendations by ACOG spelled out 
screening frequency, the screening tool preferred, EPDS, and the need for treatment and 
referrals to mental health providers when indicated (ACOG, 2016).  Discussions of the 
research showed that Ambrosini et al. (2012) developed a risk personality scale to define 
the risk factors for pregnant women in relation to maternal mental health issues, including 
perinatal and postpartum depression.  ACOG and research done by Gaynes et al. (2005) 
have similar risk factor identifiers.  Risk factors specific for perinatal depression are life 




violence, lower income, lower education, smoking, single status, and poor relationship 
quality, research showed that all pregnant women should be screened for perinatal 
depression, but that women with higher risk factors including depression and perinatal 
mood disorders warrant more frequent assessment (ACOG, 2016).  Recommendations for 
depression screening at least one time during the perinatal period is endorsed by ACOG, 
ACNM, and the USPSTF (ACOG, 2017, ACNM, 2013, Siu, 2016). The USPSTF (2016) 
considers perinatal depression as a preventable and treatable mental health problem, and 
it recommends a “B” grade for a suggestion of medical practices to offer or provide this 
service.  The “B” grade details that “The USPSTF recommends the service, there is high 
certainty that the net benefit is moderate or there is moderate certainty that the net benefit 
is moderate to substantial” (Siu, 2016, p. 1).  In January 2016, a U.S. government panel 
of medical experts recommended screening for mental health in all pregnant women, 
previous medical expert panels recommended screening, only if follow up treatment was 
available (Belluck, 2016).  In a study of nearly 9,000 perinatal women who were 
screened both during the perinatal period and the postpartum period, 7 % or 576 screened 
positive for depression during the perinatal period (Venkatesh et al., 2016).  Venkatesh et 
al. (2016) conducted their study at a large university; therefore, treatment, both through 
counseling and pharmacological, had a higher rate of compliance.  The study showed that 
more women were apt to seek and accept treatment during the perinatal period than 
during the postpartum period (Venkatesh et al., 2016).  In a study done by Goodman 
(2009), the women in the study stated that during the perinatal period, they had more time 




as reasons for not attending treatment after the birth of the child (Venkatesh et al, 2016).  
The literature supports the need for perinatal depression screening.   
Three states have mandated maternal depression screening: New Jersey in 2008; 
and Illinois and West Virginia, in 2009 (Rhodes & Segre, 2013).  The only state with a 
follow-up evaluation was New Jersey (NJ).  A study was conducted by Kozhimannil, et 
al., and reported on findings of 30,955 perinatal clients from the NJ Medicaid program. 
According to the study they “found that neither the required screening, nor the 
educational campaign that preceded it, was associated with improved treatment initiation, 
follow-up, or continued care” (Kozhimannil et al., 2011, p. 301).  Twelve states, 
including Massachusetts and New York, have tried to mandate perinatal screening but 
have been unsuccessful due to reimbursement and follow up issues that may have 
resulted in legal matters (Belluck, 2016).  
California bill AB 2193, a bill that was proposed in early 2018, would require 
OBGYN providers to screen pregnant women for mental health problems and require 
insurance companies to refer case management programs to help mothers find mental 
health care (Dembosky, 2018).  This bill is being endorsed by women with a history of 
perinatal depression, who stated that they had wished this proposed bill was in place 
when they were pregnant.  Mental health professionals are also supporting it.  
Suggestions for treatment of perinatal depression in the Dembosky blog, are counseling, 
suggested pharmaceuticals that weigh the risk-benefit during pregnancy, and follow-up 
appointments.  Perinatal preventive group therapy interventions were also studied for 




conducted a randomized controlled trial for 1,719 perinatal women in 62 antepartum 
centers.  Seven hundred and ten pregnant women were included in a four-week perinatal 
preventative group intervention therapy session.  The control group of over 1,000 
pregnant women was given the same information, but in a conventional means, by way of 
office visits and handouts.  Clients who had been diagnosed with depression during this 
study in 2012 showed a positive outcome with the perinatal preventive group therapy. 
The therapy provided coaching in stress management, improving coping skills, and 
developing social support, and it was shown to decrease symptoms of PPD. In an article 
by Latendresse et al. (2017), they discussed pharmacological treatments for women 
during both the perinatal and postpartum periods of the pregnancy.  The article covered 
the use of the EPDS, as recommended by the USPSTF, the pathophysiology of 
depression in pregnant women, the need for differential diagnosis, and the risk-benefit for 
pharmacological treatment.  The article revealed that there is not a recommended 
treatment for perinatal and postpartum depression, but that an individual approach was 
advocated.  It was concluded in the Latendresse article that although the recommended 
pharmacological treatment is not without risk, the medications suggested for depression 
during pregnancy, can be taken relatively safely as an effective treatment.  More studies 
need to be researched in the future for complications of pregnancy and to the fetus with 
the pharmacological treatment options of depression (NIMH, 2009). 
Screening for perinatal depression has shown that the EPDS is an appropriate 
screening tool.  ACOG recommends the EPDS as a valid and sensitive tool for perinatal 




Somberg, 2005).  The EPDS is recommended as the screening tool of choice by most 
researched journals and professional medical organizations ("Screening for Perinatal 
Depression - ACOG," 2016).  The USPSTF also recommends the EPDS as a sensitive 
and specific screening tool for depression and that the questions ask the perinatal client 
about depressive symptoms during the previous seven days (Latendresse, Elmore & 
Deneris, 2017).  The EPDS consists of 10 questions, it takes five minutes to complete, it 
is available in twelve languages, it has a low required reading level and is easy to score 
("Screening for Perinatal Depression - ACOG," 2016).  In a study using the EPDS during 
the perinatal period, OBGYN providers were more effectively able to treat and support 
their clients when they had a definitive EPDS score, cutoff of >13 (Wickberg, Tjus, & 
Hwang, 2005).  Six hundred sixty-nine women were included in this study and were 
given the EPDS questionnaire by 32 midwives, who also evaluated the results of the 
screening. The results effectually provided a better treatment plan due to the findings of 
the EPDS.  
A barrier for screening for perinatal depression is the resulting recommended 
treatment. In California (CA), bill 2193 is being reviewed for passage to mandate 
perinatal depression screening.  Obstetricians and Pediatricians are fighting the CA bill, 
stating that it is difficult to treat the client who’s screening is positive for depression, and 
that follow-up was challenging for the providers to attain (Dembosky, 2018).  Many 
obstacles influenced treatment, including no insurance coverage for treatment, 
medications prescribed may cause harm to the fetus, long waits for mental health 




pregnant women (Dembosky, 2018).  Physicians in CA will be disciplined for not 
screening. “Because a willful violation of the (CA) bill’s requirement by a health care 
service plan would be a crime, the bill would impose a state-mandated local program” 
(Bill Text - AB-2193 Maternal mental health, 2018, p. 1).  The World Health 
Organization (WHO), has prepared an intervention guide to help mental health providers 
with specific mental health diagnosis.  The mental health providers will have access to 
this guide, ‘mhGAP Intervention Guide,’ this guide is a model that has been developed 
by mental health care providers and integrates the management of significant conditions 
using protocols for clinical decision-making (WHO, 2010).  The guide is designed to help 
recommend guidelines of treatment for specific non-specialist health settings.  
Seventy-eight percent of the clients that screen positive for depression do not get 
treatment, as described in the blog by Dembosky, which is the reason for being proactive 
for the CA bill, it is also aligned with the study by Kelly et al. (2001) that only one in five 
women receive treatment. In the study by Kelly et al., they screened 186 women during 
their prenatal care appointments with the Primary Care Evaluation of Mental Disorders 
Patient Health Questionnaire.  Of the 186 women, 70 or 38% screened positive for 
psychiatric disorders, only 23% received treatment (Kelly et al., 2001). ACOG details 
that the perinatal screening should ensure follow up, and treatment.  According to an 
article in the Journal for Nurse Practitioners, depression symptom screening does not 
decrease perinatal or postpartum depression; follow up is essential (Selix & Goyal, 2018).   
The provider may be accustomed to prescribing pharmacological treatment, but as stated 




by healthcare providers must be prepared for screening and treatment of maternal mental 
health issues (Selix, & Goyal, 2018).  In the findings of a study done by Goodman & 
Tyer-Viola (2010), they discovered that of the 23% of women diagnosed with perinatal 
mental health issues, only 15 % of them had documented mental health follow-up care. 
The study was done in 2010 and involved 491 women from a large urban hospital.  The 
conclusion to the study found indications that detection, treatment, and referral of 
perinatal depression by obstetrical providers was seriously lacking and needed to be 
addressed (Goodman & Tyer-Viola, 2010).   
 Barriers to treatment are possible preterm births, clients not following up with 
treatment, and the cost of the screening and the treatment (Grajkowski, Dolinsky, Abbott, 
& Batig, 2016).  Treatment concerns were concurring with the National Institute of 
Mental Health (NIMH) through the NIH, that pharmacological treatment for depression 
can lead to premature birth (NIMH, 2009).  According to a study in the American Journal 
of Psychiatry (2009), the risk/benefit for treatment must be measured, “both continuous 
selective serotonin reuptake inhibitor (SSRI) exposure and continuous untreated 
depression were associated with preterm birth rates exceeding 20%” (Wisner et, al., 
2009).  This study obtained by blinded review of delivery records and infant 
examinations, of 238 women, 71 women were exposed to SSRI’s.  The study concluded 
with results showing depressed pregnant women, with both continuous SSRI exposure 
and continuous untreated depression, were associated with preterm birth rates exceeding 




In a study conducted by Goodman (2009), she found other barriers to treatment 
for perinatal depression.  She provided a questionnaire to 509 women during their third 
trimester of pregnancy and asked that if they were diagnosed with perinatal depression, in 
which form of treatment would they participate.  The results showed that 92% of the 
women would participate in individual counseling, only 35% would take medication, and 
only 14% would participate in group counseling.  In the study, Goodman also found that 
the most significant perceived potential barriers to treatment were lack of time (65%), 
stigma (43%), and childcare issues (Goodman, 2009).  Not only are cost and medication 
effects a deterrent to treatment, but also the reasons that prevent the women from 
participating in treatment.  Finding what would be acceptable and preferable treatment is 
one of the only solutions Goodman found in order to improve depression treatment rates.  
Discussion of the outcomes of the positive depression screening and the necessary 
follow-up with the pregnant women’s treatment and preferences to treatment needs to be 
accessed. 
The providers in CA, where bill 2193 is being reviewed, were also concerned 
with costs, as they were not being reimbursed for the testing.  Other states have tried to 
mandate perinatal depression screening, but it did not result in more women being treated 
(Dembosky, 2018).  “Illinois, New Jersey, and Massachusetts have created unique 
programs that can be used as exemplars for other states looking to create comprehensive 
programs to address perinatal depression” (Selix & Goyal, 2018, p.123).  More 
government-funded insurance programs are being reviewed for helping to support 




problem. In an article by Rhodes and Segre (2013), Perinatal depression: a review of US 
legislation and law, they assembled an interdisciplinary team of academics specializing in 
law, as well as perinatal mental health to help examine the subject of perinatal depression 
in the U.S.. They accessed the states that have mandated perinatal depression screenings, 
the results of the outcomes of the screenings, and the need for other states to follow 
legislative mandates. The conclusion of the article details that even though three states 
have mandated perinatal depression screenings, there is no evidence of these screenings 
decreasing perinatal or postpartum depression. In 2003 Texas enacted the Andrea Yates 
bill, which mandated perinatal depression education.  Between 2000 and 2006, NJ and 
Virginia joined Texas in adopting mandatory training for perinatal depression, and 
between 2007 to 2012, nine more States followed the procedure.  However, only 24% of 
the States have legislation that mandates for perinatal depression (Rhodes & Segre, 
2013).  Having a recommendation from ACOG, ACNM, and the NIH should improve 
reimbursement for providing the screening for perinatal depression as well as treatment 
costs.  Reviewing other states with similar bills regarding perinatal depression screening, 
is recommended for an increase in improved screening practices.  However, treatment for 
depression also must be accepted and achievable by the client.  In an article by Yu & 
Sampson, 2016, they conclude that the reason there is a problem with consistency 
regarding perinatal depression screening across the States is due to discrepancy between 
policy and practice goals, lack of regulations on capability building among perinatal care 




mental health professionals (Yu & Sampson, 2016).  Establishment of a protocol for 
screening and treatment is essential for effective client care.  
Research shows a need for perinatal depression/mental health screening.  There 
are treatments that are effective, both non-pharmacological and pharmacological.  The 
risk/ benefit must be measured for pregnant women who need medication treatments. 
Follow-up for recommended treatment is crucial.  If perinatal women are being 
diagnosed with mental health issues, a plan must be in place for follow-up.  A plan of 
care for positive screenings and treatment will included in the client’s medical records for 
tracking results.  Future research may consist of an analysis of interventions that promote 
social support to pregnant women, the need for specific screening tools for pregnant 
women, and more research on pharmacologic treatment for pregnant women. 
State/government mandated screening and treatment with appropriate follow-up and 







The OBGYN practice was only providing a postpartum depression screening at 
one to two weeks postpartum, and at six weeks postpartum, the EPDS is used for the 
post-partum depression screening.  The DNP project was a CPG change and proposed the 
implementation of the EPDS tool to assess depression symptoms in perinatal clients.  The 
literature reveals that the implementation of perinatal depression screening is being 
reviewed by many states in the U.S. to be mandated in future legislation.  Insurance 
providers are also studying evidence-based practice and guidelines for providing perinatal 
depression screenings.  Through ACOG, ACNM recommendations, and a review of 
current literature, I have encouraged the use of a depression screening tool during the 





Section 3: Clinical Practice Guidelines Development 
Introduction 
The proposal of this DNP project is promoting a CPG change to include a 
perinatal depression screening tool, specifically the EPDS, to be given to all pregnant 
women during the early perinatal period. Boyd et al. (2005) studied the soundness of the 
EPDS tool and found that it was most appropriate for postpartum women with reasonable 
psychiatric accuracy and for use during the perinatal period as well.  The Appraisal of 
Guidelines Research and Evaluation (AGREE II) is a tool that was established to create a 
generic instrument to assess the process of guideline development and reporting of this 
process (AGREE Enterprises, n.d.).  Using the AGREE II to develop the practice 
guidelines changes has increased the strength of the practice change proposed (AGREE 
Enterprises, n.d.).  This DNP project provided an opportunity to promote the CPG into 
the current clinical practice at the OBGYN office.  
The details of the CPG were presented to the OBGYN practitioner’s office at their 
weekly meeting. Statistics of perinatal and PPD were discussed.  The practitioners had 
wanted to incorporate a perinatal depression screening scale into the practice but had not 
yet had the opportunity.  After I met with the practitioners, I asked for suggestions about 
the timing of the screening.  The screening and treatment plan will become part of the 
client’s electronic health records so that the appropriate follow-up and treatment can be 
given.  
This proposal information has been discussed with the provider’s office staff and 




Moon (Fura & Silliman, 2014) has been presented to the nurses and staff. The video 
portrays the evidence and potential tragedy of postpartum depression and the need for 
perinatal screenings.  The staff was included in the project due to their interactions with 
the clients regarding perinatal appointments, follow-up appointments, and medications 
prescribed. Ideas had been discussed, and changes had been made as necessary. 
Challenges that potentially can occur with this proposed clinical practice guideline 
change, is the noncompliance of the providers and staff.  After I met with both providers 
and staff, statistics were provided to show evidence-based practice information regarding 
the need for perinatal depression screening during the perinatal period.  The need for this 
practice change is evidenced by literature and recommendations of the ACOG and 
ACNM.  Recommendations for follow-up of the clinical practice change have been made 
to the providers.  The follow up included the practice staff to review the compliance of 
the guideline change and reorient the staff as needed for the encouragement of 
implementation of the EPDS tool.  
The stakeholders for this project are the pregnant women, their families, obstetric 
healthcare providers to including physicians, nurse midwives, nurses at the obstetrical 
clinic, and nurses, staff, and administration at the women’s services department at the 
healthcare facility.  If depression or mental health problems are discovered in the 
perinatal stage, potentially mental health care providers would be stakeholders as well. 
Collaboration with the stakeholders and end-users have alleviated barriers to the project 




Description of the Development of the CPG and the Adoption of the Tool 
According to the ACOG (2017) the following observations and recommendations 
were made:   
• Although definitive evidence of benefit is limited, the American College of 
Obstetricians and Gynecologists recommends that clinicians screen patients at 
least once during the perinatal period for depression and anxiety symptoms using 
a standardized, validated tool.  
• Women with current depression or anxiety, a history of perinatal mood disorders, 
or risk factors for perinatal mood disorders warrant particularly close monitoring, 
evaluation, and assessment.  
• Although screening is important for detecting perinatal depression, screening by 
itself is insufficient to improve clinical outcomes and must be coupled with 
appropriate follow-up and treatment when indicated; clinical staff in obstetrics 
and gynecology practices should be prepared to initiate medical therapy, refer 
patients to appropriate behavioral health resources when indicated, or both.  
• Women with current depression or anxiety, a history of perinatal mood disorders, 
or risk factors for perinatal mood disorders warrant particularly close monitoring, 
evaluation, and assessment. Systems should be in place to ensure follow-up for 
diagnosis and treatment.   
The ACNM (2013) also recommend perinatal depression (PD) screening.  Although the 
ACNM first recommended PD in 2003, it was updated in 2013, but the recommendation 




(PSI) Legislation, in 2016, was the first entity to present guidelines for perinatal 
depression screening during the first prenatal visit and also during the second and third 
trimesters, continuing through the postpartum period, using either the EPDS or the PHQ-
9 (Selix, & Goyal, 2018).  My CPG was for the EPDS to be given to women during their 
confirmation of pregnancy appointment.  According to the concept in the change theory 
there are three processes in order to adopt this CPG changes at the OBGYN practice. 
Unfreezing is the first stage, the OBGYN practice realizes, through evidence-based 
practice and literature review, the need for the implementation of the depression 
screening during the early perinatal period (see Mitchell, 2013).  The second stage is 
moving: introducing the implementation of the CPG change, adding the EPDS tool to the 
OBGYN practice protocol (see Mitchell, 2013).  The last stage of the theory is refreezing.  
I have proposed the implementation of the CPG change to have the EPDS included in the 
perinatal appointment paperwork, to be made a permanent change, and establish the new 
procedure (see Mitchell, 2013).  The adoption of this tool will become part of the early 
perinatal appointment’s paperwork and part of the permanent chart.  The EPDS will be 
given to the women by the nurse or medical assistant, with an explanation that the 
practitioner will review the screening tool.  
The Expert Evaluation Panel  
I assembled an expert panel in the OBGYN field to discuss steps in order to 
evaluate and promote the CPG.  An expert panel focuses on making evidence-based 
policy judgments needed to direct the implementation of a practice request (Jonas, 




RN, MSN who teaches Maternal-Childcare in a BSN program, an RNC-OB (credential in 
inpatient obstetric nursing), MSN,  who has been a nurse manager in Women’s Health at 
various healthcare facilities and is currently the nurse manager of the Women’s Health 
unit at the local hospital, and an RNC-OB, MSN with ten years of experience in 
Women’s Health services at the local hospital, and now is also a nurse educator.  This 
panel is relevant to this Capstone project, given that they all have a stake in the CPG 
change that will be presented in their practice.  
Experts Use of Agree II to Evaluate the CPG and Tool 
Agree II is the framework that was used by the expert panel to evaluate the 
robustness and quality of the CPG.  The expert panel has received the review of the 
literature regarding the need for a depression screening tool as the CPG, and I provided 
the documented recommendations of nationally accredited organizations that promote 
perinatal depression screening.  
The expert panel was provided with information on the purposefulness and the 
intention of the CPG.  I described the stakeholders of the guideline change and the 
population who will be affected by the proposal.  I provided the panel with information 
on the appropriateness of the CPG and likely barriers of the CPG that were detected and 
then the resolutions.  I proposed the use of the EPDS as the screening tool because it is 
available at the OBGYN office.  The EPDS is free and it is an easy read and scored tool. 
Expert panels are the final process used for gaining understanding into what experts 
believe about the implications of the evidence for a given treatment or practice change 




Revision of the Guideline and Tool, Based on Feedback from Experts 
Following the expert panel evaluation and critique, I had made changes to my 
proposed CPG.  Relying on the expert opinions and their review of the review of the 
literature and recommendations of the ACOG, and ACNM,  I used their analysis of the 
CPG and revised it to be more aligned with the Agree II  framework, the expert panels 
suggestions and recommendations of  what worked and what will not at the OBGYN 
practice site.  Since the expert panel works with the CPG change during practice,  they 
know the routine of the healthcare staff of the practice, they are able to foresee potential 
changes that could be made to make the change less stressful, have fewer hindrances, and 





Section 4: Findings and Recommendations 
Introduction 
This doctoral project was a CPG concerned with evaluating the need for 
depression screening during the perinatal period.  The gap-in-practice was the lack of a 
guideline in using and addressing a time frame in order to screen for depression during 
the perinatal period.  The Agree II instrument was used to evaluate the CPG.  Agree II is 
a tool created to access the practical quality of practice guidelines (AGREE Enterprises, 
2013).  Using the AGREE II tool to evaluate this CPG assured that the guidelines were 
rigorously evaluated and were found sound and that this guideline could potentially be 
recommended for use at other healthcare facilities.  A group of three experts in the 
obstetrics field of nursing volunteered to evaluate the CPG; they were given the 
Disclosure to Expert Panelist Form for Anonymous Questionnaires acquired from the 
Walden University Institutional Review Board (IRB).  The expert panel consists of three 
nurse leaders with proficiency in obstetrics and gynecology disciplines.  Panel Expert 1 is 
a nurse educator, RN, MSN who teaches Maternal-Childcare to BSN students at a local 
university. Panel Expert 2 is an RNC-OB, MSN, and has been a nurse manager in 
Women’s Health at various healthcare facilities and is currently the nurse manager of the 
Women’s Health unit at the local hospital. Panel Expert 3 is an RNC-OB, MSN with 10 
years of experience in Women’s Health Services at the local hospital, and now is also a 
nurse educator.  This expert panel was asked to assist me with the evaluation of my DNP 
project CPG due to their experience in women’s health, and they volunteered to complete 




II instrument and the user’s guide.  The expert panel reviewed the six domains and 23 
target items of the Agree II tool.  Each section was rated by a score from 1-7, with 1 not 
meeting the criteria of the Agree II item, and 7, the criteria of the item was fully met.  
Findings and Implications 
The AGREE II scale was used to measure the extent to which a criterion has been 
fulfilled in the development of the proposed guideline for the use of the EPDS during the 
early perinatal period.  The results of the AGREE II scale are shown in Table 1.  The 
percentage scores are a result of adding up the scores associated with each of the AGREE 
II’s six domains and using the scoring recommended by the AGREE II manual.  The 
expert panel scored the evidence-based recommendations and also provided qualitative 












AGREE II Data for the CPG: Screening for Depression During the Early Perinatal 
Period 
AGREE II Domain % of Appraiser agreement 
Domain 1- Scope and Purpose  94% 
Domain 2- Stakeholder Involvement  94% 
Domain 3- Rigor and Development  94% 
Domain 4- Clarity of Presentation  94% 
Domain 5- Applicability  94% 
Domain 6- Editorial Independence  86% 
Overall Guideline Assessment  92.6% 
Recommendation of guidelines for use  100% Yes, without modifications 
 
The results of applying the AGREE II instrument’s six quality domains to the 
CPG were assessed using the questionnaire, which contributed to the data information for 
this DNP project.  The following is a summarization of the AGREE II description and 
results from Table 1, retrieved from the Appraisal of Guidelines for Research & 
Evaluation II instrument (2013).  Domain 1: Scope and practice, the CPG should show 
that the health question and overall objectives of the guidelines were specifically 
described (AGREE Enterprises, 2013).  Comments from evaluators on Domain 1 related 
that the objectives were clearly described, the healthcare concern and question were 




Stakeholder involvement, ensures that all personal relevant to the project and clients 
affected by the guidelines were included in the development of the guidelines (AGREE 
Enterprises, 2013).  Domain 3: Rigor of development confirms that evidence-based 
sources were used to develop the CPG and that there is a relationship between the sources 
of evidence and the recommendations of the CPG (AGREE Enterprises, 2013).  
Comments for Domain 3 detailed that the benefits and risks of the CPG were fully 
discussed, and that an expert panel reviewed the material prior to publication.  Domain 4: 
Clarity of presentation, discusses that the recommendations of the CPG are specific and 
identifiable and that healthcare options are presented for the CPG (AGREE Enterprises, 
2013).  The comments for Domain 4 clarify that the recommendations described in the 
CPG were clear and specific to the project.  Domain 5: Applicability, tools for the CPG 
are present and barriers to the application were discussed (AGREE Enterprises, 2013). 
Comments for Domain 5 were that the tool that was recommended for application to 
practice was discussed and furnished the guidelines on how and when to use the tool 
were provided.  Domain 6: Editorial independence, describes that there are guidelines in 
place to prevent a conflict of interest in either the funding or competing interest of the 
CPG (AGREE Enterprises, 2013).  Domain 6 was graded the lowest score, with an 
average of 86%.  The reviewer was either not able to extract the source of the funding or 
was not able to assess any conflicting interest of the CPG.  This CPG’s overall guidelines 
assessment had a 92.6% overall appraiser agreement, “the data for ‘Overall Guideline 
Assessment’ can be calculated with high reliability using a standardized score” (Seto, 




The project goal was to evaluate the need for the use of the EPDS during the 
perinatal period and it was met.  IRB approval was achieved, and no human subjects were 
involved in this project. 
Revision of CPG Based on Recommendations 
The findings of this DNP project confirmed, through the use and results of the 
AGREE II tool, that there was a gap-in-practice of OBGYN providers not using a 
depression screening during the early perinatal period.  Both the ACOG and the ACNM 
recommend the use of a depression screening tool during the perinatal period (ACOG, 
2017).  The CPG solution to this gap-in-practice was the necessity of providing a 
depression screening tool, specifically the EPDS questionnaire, to be given to women 
during their early perinatal period.  The CPG has been developed and, once implemented, 
guidelines will be in place for the use of the EPDS, with recommendations for the timing 
of the screening.  
A revision of the CPG, specifically domain # 6, editorial independence, was 
addressed due to the comments by the expert panel.  Complying with recording and 
addressing any competing interest and funding have not influenced the CPG.  The writer 
of this CPG does not have any influence over the implementation of the use of the 
screening, and the EPDS is a free screening tool available on the internet.  
Key stakeholders for this CPG are the practitioners, healthcare employees at 
OBGYN practice offices, and perinatal clients.  The practicum site referred to in this 
CPG has three full-time OBGYN physicians and five Certified Nurse Midwives.  The 




overall quality of the CPG project.  She is willing to proceed with implementing the 
CPG, with one change in mind.  The practice would change the early perinatal depression 
screening tool to be used at the 12-week appointment instead of the confirmation of 
pregnancy appointment, as portrayed in this DNP project.  The OBGYN practice did not 
have the depression screening ordered during the perinatal period, which was the gap-in-
practice that prompted this DNP CPG project.  As per the main OBGYN practitioner at 
the practicum site, the EPDS screening will be part of the intake form for OBGYN clients 
during their 12-week check-up appointment.  It will become part of the client’s healthcare 
records. 
Overall safety for the perinatal client is the most important reason for this CPG. 
The news conveys frequent reports of perinatal and postpartum depression related to 
violent incidences.  If by implementing this CPG, it can help one mother and fetus from a 
tragedy, then this project will have been a success. 
Strengths and Limitations of the Project 
The strength of this DNP project was the ongoing involvement of the leadership 
and expert panel members.  They assisted in the commitment to develop a guideline for 
this gap in practice.  The overall quality of this CPG was given the highest possible grade 
from the expert panel.  Overall guideline assessment by the expert panel recommended 
the CPG by 100% agreement.  Comments were that there is a much-needed application of 
available tools/ information in the specified client population and that for one reviewer 




for this CPG in the gap in practice for client safety in the necessity of a perinatal 
depression screening. 
The limitation of this project was that this practice guideline was developed for a 
small private OBGYN practice in a suburban Texas town.  State regulations and 
guidelines may vary from state to state, private versus public practice, and the size of the 
practice.  As a result, this CPG may need to be modified or adapted to be appropriate for 
various OBGYN practices in other states.  However, the guidelines followed for this CPG 
were recommendations from American associations of ACOG and the ACNM.  
Recommendations for future projects with a similar topic could include screening 
antenatally for depression and mental health issues so that practitioners would be more 
alert to providing depression screenings during the pregnancy. “Although there are risk 
factors for perinatal depression and interventions exist that may help prevent perinatal 
depression, the effectiveness of these interventions and the subpopulations who could 
most benefit need further evaluation” (OConnor, Senger, Henninger, Coppola, & Gaynes, 





Section 5: Dissemination Plan 
According to Zaccagnini and White (2011), there are two purposes to 
disseminating the results of a DNP project: (a) report the results of the project to the 
stakeholders and leaders and (b) share them with other professionals in similar settings. 
The information and data obtained in this DNP project were disseminated to the 
practicum site experiencing the gap-in-practice.  The dissemination of this project 
included presenting the CPG to a local OBGYN practice office for review and eventual 
integration of the guidelines.  The results of the CPG DNP project were reviewed with 
key stakeholders of the practicum site as well as the nurses and staff.  
The audience for this CPG DNP project was the OBGYN practitioners, office 
staff, and pregnant clients.  The purpose of this CPG was to propose the use of a 
depression tool during the early perinatal period.  The use of the EPDS tool has been 
established as a reliable tool for use during the perinatal period (Gibson et al., 2009). 
With the assistance of the expert panel and the evaluation of the CPG with the Agree II 
tool, this will give acceptance and provide an evidence basis for the need for this practice 
change.  
The key stakeholders, practitioners, and staff members will benefit from the 
findings because the information provided to them is in the form of a poster presentation, 
available at the practicum site.  Another option for the dissemination of this DNP project 
would be to submit an abstract to a scholarly journal for a potential article publication. 
Publishing this DNP project in a scholarly journal would allow for broader dissemination 




preparing and developing the CPG will be beneficial to individuals interested in 
preventing depression during the perinatal period. 
A CPG can improve the quality of decisions made by clinicians.  The guideline 
offers a clear recommendation based on evidence-based practice.  A CPG can improve 
the consistency of care and provide reliable recommendations that support the 
practitioner’s concerns about the appropriateness of their medical treatment policies. 
Guidelines based on evidence-based practices can clarify which interventions are proven 
beneficial and verify the quality of the supporting data (Woolf, Grol, Hutchinson, Eccles, 
& Grimshaw, 1999).  Dissemination of this DNP project to similar OBGYN practices and 
women’s healthcare facilities would provide an evidence basis for providing perinatal 
depression screenings.   
A CPG can help patients by influencing public policy (Woolf et al., 1999). 
Guidelines call attention to less recognized health problems and preventive interventions. 
Services that were not previously offered to patients may be made available as a response 
to newly released guidelines and CPG’s that are developed with attention to the public’s 
benefit can promote equal fairness, and advocate for better delivery of services (Woolf et 
al., 1999).  According to the USPSTF’s most recent recommendations, there is a 
moderate net benefit for perinatal depression screening leading to counseling 
interventions to prevent perinatal depression (OConnor et al., 2019).  There are many 
resources and documentation for postpartum depression, but a limited amount on 
perinatal depression. Perinatal depression is a less recognized health problem, but with 





Analysis of Self 
The reason I chose this topic was that I felt there was limited information 
regarding depression screening during the perinatal period.  The gap in literature shows a 
lack of evidence-based practice regarding perinatal women and depression screening. 
With the promotion of this guideline, I hope to increase the use of depression screening to 
perinatal women in OBGYN practices, in order to expand this critical CPG.  I believe this 
guideline would be beneficial to others outside of my practicum setting and by submitting 
this CPG to a peer-reviewed nursing journal with a focus on the topic of obstetrical 
nursing.  
My role at this time is to continue to educate the practitioners, nurses, staff 
involved in caring for pregnant women as well as the clients, in order to provide a safer 
environment for the pregnant woman, her infant, and her family.  As a nurse educator, I 
will also discuss the CPG DNP project and the outcomes I have discovered after 
researching this topic with my nursing students.  I have shown the documentary, Dark 
Side of the Full Moon (Fura & Silliman, 2014), during my maternity course, and I will 
continue to do so.  I have had many students comment on this documentary that they had 
not realized the ramifications and the actual disease process of depression during and 
after pregnancy. 
Summary 
After reviewing the results of the AGREE II score and discussing the findings 




the DNP CPG project.  Through research and discussions, the need for this practice 
change was evident. Preceptors and key stakeholders had been discussing the need for the 
proposed project.  Guidance was needed to assist in formulating a practice guideline for 
this gap-in-practice. ACOG and ACNM have recommendations for the necessity for a 
perinatal depression screening, but it was not a regulation.  OBGYN and women’s health 
practices were meant to interpret the recommendations as needed.  After reading blogs 
and articles from pregnant and post-partum women, it was obvious that a reliable 
guideline was needed.  
Throughout this project, I worked closely with nurses and practitioners from the 
practicum site.  According to Melnyk (2013), the DNP scholarly project should focus on 
translating “research findings into clinical practice or policy to positively influence health 
care and patient and policy outcomes” (Melnyk, 2013, p. 444).  The focus of the CPG 
was to propose the use of a depression screening tool during the early perinatal period.  
Sharing the developed clinical practice guideline with the practicum site may increase the 
likelihood of them adopting evidence-based practices and improved patient care practices 
regarding depression screenings. 
This DNP project was a CPG that addressed a gap in practice and proposed to 
provide a safe resolution for perinatal clients.  The lack of guidelines in using a 
depression screening tool during the perinatal period is not only a national priority but 
also an international one, as discussed on the World Health Organization’s website for 
maternal health and the research done for this project.  The project outlined the gap-in-




to use a depression screening tool during the perinatal period.  The goal of this DNP 
project was to develop the CPG for use at the practicum site. Safe management of the 
client is the optimal outcome for all clients in order to achieve better treatment outcomes. 
The practicum site is associated with a mid-sized medical facility, including a large 
women’s health department.  Dissemination of this CPG to key stakeholders at the 
medical facility, including the nurses and staff in the Women’s health department, 
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Appendix A: Proposed Clinical Practice Guideline Change 
All pregnant women in a rural OBGYN office in South Texas will receive the 
Edinburgh Postpartum Depression Screening tool during the early perinatal period; 
‘confirmation of pregnancy appointment. The proposal will be reviewed by an expert 
panel of healthcare professionals with specialties in the OBGYN practice and by using 





Appendix B: Edinburgh Postnatal Depression Scale (EPDS) 
Name:                                 Date:                      
 
We would like to know how you are feeling. Please UNDERLINE the answer which comes closest to 
how you have felt IN THE PAST 7 DAYS, not just how you feel today. 
 
Here is an example, already completed. 
 
I have felt happy: Yes, all the time Yes, most of the time No, not very often No, not at all 
 
This would mean: “I have felt happy most of the time” during the past week. Please complete the other 
questions in the same way. 
 
 
In the past 7 days: 
1. I have been able to laugh and see the funny side of 
things 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all 
 
*6. Things have been getting on top of me 
Yes, most of the time I haven’t been able to 
cope at all 
Yes, sometimes I haven’t been coping as well 
as usual 
No, most of the time I have coped quite well 
No, have been coping as well as ever 
 
2. I have looked forward with enjoyment to things 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 
*7. I have been so unhappy that I have had difficulty 
sleeping 
Yes, most of the time 
Yes, sometimes 
Not very often 
No, not at all 
 
*3   .I have blamed myself unnecessarily when things 
went wrong 
Yes, most of the time 
Yes, some of the time 
Not very often 
No, never 
*8. I have felt sad or miserable 
Yes, most of the time 
Yes, quite often 
Not very often 
No, not at all 
 
4. I have been anxious or worried for no good reason 
No, not at all 
Hardly ever 
Yes, sometimes 
Yes, very often 
*9   I have been so unhappy that I have been crying 
Yes, most of the time 




*5. I have felt scared or panicky for no very good 
reason 
Yes, quite a lot 
Yes, sometimes 
No, not much 
No, not at all 
*10. The thought of harming myself has occurred to me  









Appendix C: Pregnancy-associated Suicides*: Demographics compared to all Live Births 
 
Pregnancy-Associated 
Suicidesa n (%) 




   
 15–19 12 (12.8) 456,478 (9.5) 0.27 
 20–24 18 (19.1) 1,153,503 (24.1) 0.26 
 25–29 19 (20.2) 1,296,074 (27.1) 0.13 
 30–39 29 (30.8) 1,746,560 (36.5) 0.25 




   
Race/Ethnicityc 
   
 Non-Hispanic 
White 
70 (74.5) 2,837,502 (59.4) <.01 
 Non-Hispanic 
Black 
11 (11.3) 845,448 (17.7) 0.10 
 Hispanic 7 (7.2) 780,470 (16.3) 0.02 
 American Indian 5 (5.1) 76,131 (1.6) <.01 
Unmarried 57 (58.8) 1,267,030 (34.7) <.01 
*pregnancy-associated=deaths occurring during pregnancy or the first year postpartum 
an=94 
ccells suppressed for other races due to low number of cases; Asian/Pacific Islander 
Reference: Palladino et al., 2011 
 
